Cequa™ - Dry Eye Syndrome

Cequa™ is a patented nanomicellar cyclosporine solution for topical ophthalmic administration, discovered and developed by Auven Therapeutics for the treatment of dry eye syndrome. Cequa™ was sold to Sun Pharmaceuticals, and was subsequently approved in in the USA for Dry Eye Syndrome. Sun retains worldwide rights to the product, and Cequa™ will be launched in the USA soon.

Dry Eye Syndrome

Dry Eye Syndrome is a chronic inflammatory ocular disease that is thought to affect more than 12 million Americans. It is most prevalent in post-menopausal women and in the elderly, but all age groups can be affected. Dry eye syndrome is generally characterized by debilitating symptoms that, if left untreated, can result in blurred vision or even vision loss. An effective, well-tolerated product with relatively rapid onset of action would address the large underserved segment of the dry eye population who have not responded to currently available therapies.

Cequa™ may also address a number of other important medical conditions thought to be responsive to topical cyclosporine therapy including blepharitis, ocular rosacea, atopic keratoconjunctivitis, vernal keratoconjunctivitis, scleritis, prophylaxis of corneal transplant rejection and ocular manifestations of graft-versus-host disease.

U.S. sales of Restasis™ (another Cyclosporine Dry Eye treatment) exceeded $1.2B in 2014. However, the potential market is likely several times that.